Donetsk’s suburb comes under shelling by Ukrainian troopsWorld October 22, 4:16
Russia to host 2018 FIFA World Cup at highest level — MutkoSport October 22, 2:12
Wolf chosen as mascot of 2018 FIFA World Cup in RussiaSport October 22, 2:00
Warming in Russian-British relations not in sight over short term, says expertRussian Politics & Diplomacy October 22, 1:38
Ceasefire agreements signed with 15 more Syrian settlements — Russian Defense MinistryWorld October 22, 0:39
Russian State Duma speaker confirms readiness to meet PACE presidentRussian Politics & Diplomacy October 22, 0:15
Ukraine’s new anti-Russian sanctions to take effect on October 31World October 21, 21:22
Kremlin says Egypt’s rumored sale of Mistrals for $1 is ‘utter nonsense’Russian Politics & Diplomacy October 21, 21:13
Source: Mi-8 helicopter with 22 people onboard makes crash landing in YamalSociety & Culture October 21, 20:15
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.